Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.

Latest From Alaric DeArment

Pfizer's Elrexfio Shows Long-Term OS, But Convenience Counts Too

The drug maker presented data from the pivotal Phase II trial at EHA showing median OS of more than two years for Elrexfio.

ImmunoOncology Clinical Trials

Sarepta Retains DMD Gene Therapy Lead As Pfizer Stumbles

Pfizer’s Phase III CIFFREO study in DMD failed to meet primary and key secondary endpoints, likely removes it as a potential competitor to Sarepta’s Elevidys.

Gene Therapy Clinical Trials

ASCO: Regeneron Shows Early Bispecific Antibody Efficacy In Hard-To-Treat Colorectal Cancer

Scrip talked to Regeneron at ASCO about REGN7075 and Regeneron’s bispecific development strategy in solid tumors.

ASCO Business Strategies

Vir Hopes To Take On Gilead’s Hepcludex After Positive Early Hepatitis D Results

The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.

Clinical Trials Biologics

ASCO: As FDA’s Zolbetuximab Decision Looms, Astellas Looks To Meet Testing Challenge

Scrip sat down with Astellas chief medical officer Tadaaki Taniguchi to talk about the drug maker’s plans for taking its Claudin18.2-targeting drug to the US market.

ASCO Cancer

ASCO: Merck Calls V940 IO Strategy ‘Pillar’ Amid Positive Melanoma Data

Follow-up data from Merck & Co./Moderna’s KEYNOTE-942 showed durable responses to V940/Keytruda, while Merck said the therapy plays a leading role in its immuno-oncology strategy.

ASCO Business Strategies
See All
UsernamePublicRestriction

Register